GlassScriptPhysician profile
Roger Chi-Che Lee
NPI 1538318704
$2,576.81
in general payments reported to CMS, 2019-2025
18 companies · $1,312 in 2025
The $1,312 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $290 · 2020: $42.74 · 2021: $26.15 · 2023: $140 · 2024: $766 · 2025: $1,312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,941 · Education: $278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,940.87 |
| Education | $277.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $365.52 | 2019-2025 | Dupixent |
| Abbvie INC. | $323.43 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $323.12 | 2025 | Zoryve |
| Ucb, INC. | $277.32 | 2024-2025 | Bimzelx |
| Nevro Corp. | $198.62 | 2019 | |
| Incyte Corporation | $190.99 | 2024-2025 | Opzelura |
| Galderma Laboratories, L.P. | $185.72 | 2024-2025 | Nemluvio |
| Lilly USA, LLC | $161.96 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Organon LLC | $123.61 | 2025 | Vtama, Nexplanon |
| Sun Pharmaceutical Industries INC. | $117.72 | 2025 | |
| Pfizer INC. | $82.77 | 2023-2025 | |
| Amgen INC. | $72.42 | 2024-2025 | Otezla, Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $40.14 | 2019-2024 | Jublia, Cabtreo, Arazlo |
| E.R. Squibb & Sons, L.L.C. | $36.09 | 2024 | Sotyktu |
| Dermavant Sciences, INC. | $26.51 | 2024 | Vtama |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $20.42 | 2020 | |
| Almirall LLC | $16.80 | 2025 | Klisyri |
| Leo Pharma INC. | $13.65 | 2024 | Adbry |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.